RESUMEN
Both synthetic and natural estrogens have been studied for their ability to induce renal carcinomas in castrated male hamsters after 9.0 months of treatment. Tumor foci were detected in frozen serial sections stained histochemically for estrase activity. Both diethylstilbestrol (DES) and 17 beta-estradiol had equal ability (100%) to induce renal tumors [approximately 20.5 +/- 3 (S.E.) tumor foci] in these animals. Hexestrol induced the same incidence and number of renal carcinoma foci as DES or 17 beta-estradiol. However, alpha -dienestrol and DES 3,4-oxide showed an 86 to 88% incidence of renal tumors in hamsters (approximately 10.8 +/- 3). When equilin and d-equilenin, components of therapeutic conjugated estrogens, were tested, only equilin had a 76% incidence of renal tumor foci (5.5 +/- 0.9). The ability of these stilbene and steroidal estrogens to compete for renal tumor estrogen receptor generally correlated well with their ability to cause renal tumorigenesis in the hamster with one notable exception. Although ethinyl estradiol competed as well as did DES or 17 beta-estradiol for estrogen receptor, had similar ability to induce renal progesterone receptor, and led to similar high serum prolactin levels as either DES or 17 beta-estradiol, it had only weak carcinogenic activity (21%) in the hamster kidney (0.6 +/- 0.5 foci). These data represent the first detailed analysis of the relative carcinogenic activity of different estrogens within a given tumor-inducing system, and based on the carcinogenicity data of hexestrol and alpha-dienestrol presented herein, they suggest that epoxidation of the olefinic double bond and the p-quinone metabolite of DES probably are not involved significantly in its carcinogenic activity. Moreover, the poor carcinogenic activity of ethinyl estradiol in this system, despite strong estrogenicity, suggests that estronic activity alone may not be sufficient to effect renal tumorigenesis in the hamster.
Asunto(s)
Adenocarcinoma/inducido químicamente , Carcinógenos , Congéneres del Estradiol/toxicidad , Estrógenos/toxicidad , Neoplasias Renales/inducido químicamente , Adenocarcinoma/metabolismo , Animales , Castración , Cricetinae , Evaluación Preclínica de Medicamentos , Implantes de Medicamentos , Neoplasias Renales/metabolismo , Masculino , Mesocricetus , Receptores de Estrógenos/metabolismo , Relación Estructura-Actividad , Factores de TiempoAsunto(s)
Somatostatina/análisis , Animales , Reacciones Antígeno-Anticuerpo , Bioensayo , Encéfalo/ultraestructura , Química Encefálica , Femenino , Técnica del Anticuerpo Fluorescente/métodos , Cobayas/inmunología , Histocitoquímica , Humanos , Hipotálamo/análisis , Hipotálamo/ultraestructura , Métodos , Especificidad de Órganos , Ratas , Coloración y Etiquetado , Estómago/análisis , Estómago/ultraestructuraRESUMEN
Parathyroid hormone, injected daily in low dosage, exerted anabolic effects on the human skeleton, just as it does in the rat. Four postmenopausal women with primary osteoporosis were treated for six months with a synthetic fragment of human parathyroid hormone (hP.T.H. 1-34), given as a daily injection of 100 mug. This treatment caused a remarkable acceleration of bone turnover, indicated both by isotopic tracer and histological methods. At this normocalcaemic dose level, the increases in bone formation outweighed increases in resorption. Three of the four patients showed more positive calcium balances, and mean increases in calcium and phosphorus balances were statistically significant for the group as a whole, the changes being principally due to increased intestinal absorption of both elements. Many modifications of the present method of hormone administration are possible which could further increase the preponderance of anabolic effects. These results suggest that low doses of hP.T.H. 1-34, alone or in combination with other agents, may prove useful in the treatment of osteoporosis.
Asunto(s)
Huesos/metabolismo , Osteoporosis/tratamiento farmacológico , Hormona Paratiroidea/administración & dosificación , Absorción , Fosfatasa Alcalina/metabolismo , Resorción Ósea , Lesiones Encefálicas/diagnóstico , Calcio/administración & dosificación , Calcio/análisis , Calcio/metabolismo , Heces/análisis , Femenino , Fémur/análisis , Humanos , Ilion/patología , Riñón/metabolismo , Magnesio/metabolismo , Persona de Mediana Edad , Osteoporosis/metabolismo , Hormona Paratiroidea/fisiología , Hormona Paratiroidea/uso terapéutico , Fosfatos/metabolismo , Fósforo/metabolismo , Factores de TiempoRESUMEN
Cell bodies of small to moderate-sized neurons in the female rat hypothalamus were stained specifically for somatostatin (SRIF) by means of the unlabeled antibody-peroxidase-antiperoxidase immunocytochemical method. SRIF-positive perikarya were scattered throughout the periventricular nucleus in a limited region extending from the middle of the optic chiasm to the rostral margin of the median eminence. The same neurons were revealed with either rabbit (R) or guinea pig (GP) anti-SRIF antisera. Positive cell bodies were more readily assessed with GP antibodies because nonspecific background staining was much less with these than with R anti-SRIF. Positive perikarya were not observed in other hypothalamic nuclei and ependymal elements were also immunocytochemically negative.